ArticleClinical & experimental metastasis1999
Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma.
Article in Clinical & experimental metastasis, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Statins use and the risk of all and subtype hematological malignancies: a meta-analysis of observational studies.Cancer medicine · 2015Pooled it
- Statin use is associated with reduced risk of haematological malignancies: evidence from a meta-analysis.PloS one · 2014Pooled it
- Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies.British journal of clinical pharmacology · 2007Pooled it
- Role of PCSK9 in hallmarks of cancer: From mechanisms to interventions (Review).Oncology letters · 2026Review
- Statins as anti-tumor agents: A paradigm for repurposed drugs.Cancer reports (Hoboken, N.J.) · 2024Review
- Marketed drugs used for the management of hypercholesterolemia as anticancer armament.OncoTargets and therapy · 2017Review
- Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27-28 May, 2016, Rosario, Argentina.Ecancermedicalscience · 2016Article
- Exploiting the critical perioperative period to improve long-term cancer outcomes.Nature reviews. Clinical oncology · 2015Review
- Association between statin use and cancer: data mining of a spontaneous reporting database and a claims database.International journal of medical sciences · 2015Article
- Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy.World journal of urology · 2015Article
- Lovastatin inhibits human B lymphoma cell proliferation by reducing intracellular ROS and TRPC6 expression.Biochimica et biophysica acta · 2014Article
- Antiangiogenic mechanisms of simvastatin in retinal endothelial cells.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2010Article
- Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer.Cancer science · 2008Article
- Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins.Diabetes · 2008Article
- Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells.Molecular cancer therapeutics · 2003Article
- Hsp25 and Hsp70 in rodent tumors treated with doxorubicin and lovastatin.Cell stress & chaperones · 2003Article
- HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis.Leukemia · 2002Review
- Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.Clinical & experimental metastasis · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The HMGCoA reductase inhibitor Lovastatin (LOV) has previously shown to abrogate p21ras farnesylation, which is associated with invasive and metastatic abilities in many tumor models. Considering the scarcity of therapeutic resources against metastasis, our objective was to study LOV as an antimetastatic agent on L-TACB rat lymphoma, which as a syngeneic tumor model resembles more closely the situation in human cancer. We also aimed to analyze the effect of LOV on chemoinvasion, motility, metalloproteases secretion, angiogenic capacity, and adhesion to the reconstituted basement membrane Matrigel. Our results showed that LOV caused no effect on cell motility, metalloprotease secretion and neovascularization. Conversely, LOV produced a significant inhibition of invasiveness, which could be a consequence of an impaired cell adhesion to the basement membrane observed. These effects could explain, at least in part, the inhibitory action of LOV on L-TACB rat lymphoma metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.